These authors contributed equally to this work.
High transduction efficiency of circulating first trimester fetal mesenchymal stem cells: potential targets for in utero ex vivo gene therapy
Article first published online: 22 DEC 2003
BJOG: An International Journal of Obstetrics & Gynaecology
Volume 109, Issue 8, pages 952–954, August 2002
How to Cite
Campagnoli, C., Bellantuono, I., Kumar, S., Fairbairn, L. J., Roberts, I. and Fisk, N. M. (2002), High transduction efficiency of circulating first trimester fetal mesenchymal stem cells: potential targets for in utero ex vivo gene therapy. BJOG: An International Journal of Obstetrics & Gynaecology, 109: 952–954. doi: 10.1111/j.1471-0528.2002.t01-1-02011.x
- Issue published online: 22 DEC 2003
- Article first published online: 22 DEC 2003
- Accepted 10 June 2002
We recently reported the existence of fetal mesenchymal stem cells in first trimester fetal blood. Here we demonstrate that fetal mesenchymal stem cells from as early as eight weeks of gestation can be retrovirally transduced with 99% efficiency without selection. Circulating fetal mesenchymal stem cells are known to readily expand and differentiate into multiple tissue types both in vitro and in vivo, and might be suitable vehicles for prenatal gene delivery. With advances in early fetal blood sampling techniques, we suggest that genetic disorders causing irreversible damage before birth could be treated in utero in the late first/early second trimester by genetically manipulated autologous fetal stem cells.